Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  cobimetinib
Find trials that include:  Any drugs shown
Results 1-10 of 10 for your search:
Start Over
A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: GH29914, NCI-2016-00260, 2015-003386-28, NCT02670044
Cobimetinib and Vemurafenib in Treating Patients with Melanoma That Has Spread To the Brain
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 13-123, NCI-2015-00016, ML29155, NCT02230306
A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29479, NCI-2015-00443, 2014-002230-32, NCT02322814
Cobimetinib in Treating Patients with Histiocytic Disorders
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-216, NCI-2016-00061, NCT02649972
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GP28384, NCI-2012-01880, 2012-002738-35, NCT01656642
A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29030, NCI-2014-00008, 2013-001910-14, NCT01986166
Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GP28363, NCI-2014-00166, 2013-003329-27, NCT01988896
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29653, NCI-2015-00884, 2015-000092-27, NCT02457793
iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 to 30
Trial IDs: GO29665, NCI-2016-00541, 2014-004685-25, NCT02639546
Vemurafenib and Cobimetinib in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: J1517, NCI-2015-01387, CIR00013140, NCT02427893
Start Over